Finance

Lists
Why is CRL down २.७७%?
Dive Deeper
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
US$ २८६.८३
-२.७७%
(-८.१८) 1D
US$ २८६.८३
०.००% (०.००)
After hours
Closed: अक्टोबर १, १६:००:०७ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
US$ २९१.८६
High
US$ २९७.००
Low
US$ २८४.६१
Mkt. cap
१३.६९ अरब
Avg. vol.
९.४६ लाख
Volume
०.००
52-wk high
US$ ३०३.३०
52-wk low
US$ १४६.२०
EPS
-US$ ४.८५
Beta
१.४०
Shares outstanding
४.७७ करोड
No. of employees
१९ हजार
Open
US$ २९१.८६
High
US$ २९७.००
Low
US$ २८४.६१
Mkt. cap
१३.६९ अरब
Avg. vol.
९.४६ लाख
Volume
०.००
52-wk high
US$ ३०३.३०
52-wk low
US$ १४६.२०
EPS
-US$ ४.८५
Beta
१.४०
Shares outstanding
४.७७ करोड
No. of employees
१९ हजार
News stories
From web sources and news partners
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees१९ हजार
Founded१९४७
HeadquartersWilmington, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Websitecriver.com
Analyst ratings
Based on 17 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
15
Hold
2
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current US$ २८६.८३
US$ ३५७.०० (+२४.४६%)
Average
US$ ३१३.१३ (+९.१७%)
Lowest
US$ २१९.०० (-२३.६५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kevin Caliendo
UBS
Buy
Initiated
US$ ३५७.००
+२४.५%
09/30/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
-
-
09/28/2026
David Windley
Jefferies
Buy
Maintained
US$ ३४०.००
+१८.५%
09/28/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
US$ ३२०.००
+११.६%
09/25/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
US$ ३३०.००
+१५.१%
09/25/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
US$ २९५.००
+२.८%
09/25/2026
Ryan Halsted
RBC Capital
Buy
Maintained
US$ ३२२.००
+१२.३%
09/25/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
US$ ३३४.००
+१६.४%
09/25/2026
Luke Sergott
Barclays
Buy
Maintained
US$ ३३०.००
+१५.१%
09/24/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
US$ ३२५.००
+१३.३%
09/25/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/24/2026
Unknown Analyst
Stephens
Buy
Initiated
US$ ३२०.००
+११.६%
09/22/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
US$ ३००.००
+४.६%
09/21/2026
David Toung
Argus Research
Buy
Reiterated
US$ ३३०.००
+१५.१%
09/16/2026
Casey Woodring
J.P. Morgan
Buy
Upgraded
US$ ३१०.००
+८.१%
08/05/2026
Michael Luo CFA
CLSA
Hold
Downgraded
US$ २१९.००
-२३.६%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
US$ २६५.००
-७.६%
07/08/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Charles Weston
RBC Capital
Buy
Initiated
US$ २१५.००
-२५%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
US$ १७५.००
-३९%
02/25/2026
Last report
२०२६ अगस्ट ५
Fiscal period
Q2 2026
EPS / Est. (USD)
US$ ३.०२ / US$ २.७३
+१०.६५%beat
Revenue / Est. (USD)
१.०० अरब / ९७.७२ करोड
+२.७५%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१.०० अरब
९९.४२ करोड
९९.५८ करोड
१.०० अरब
Cost of goods sold
६५.२७ करोड
६६.५४ करोड
६७.२८ करोड
६२.५१ करोड
Cost of revenue
६५.२७ करोड
६६.५४ करोड
६७.२८ करोड
६२.५१ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१७.३६ करोड
१९.२० करोड
१४.९१ करोड
२१.४२ करोड
Operating expense
२०.१० करोड
२८.४० करोड
१६.४५ करोड
२२.७३ करोड
Total operating expenses
८५.३८ करोड
९४.९४ करोड
८३.७३ करोड
८५.२३ करोड
Operating income
१५.११ करोड
४.४८ करोड
१५.८६ करोड
१५.१७ करोड
Other non operating income
-२.२६ करोड
२.७७ करोड
-१२.३१ करोड
२.६० करोड
EBT including unusual items
८.७२ करोड
-२९.४१ करोड
-२.९९ करोड
५.३२ करोड
EBT excluding unusual items
१०.४५ करोड
३.५२ करोड
८६.२० लाख
१४.८४ करोड
Income tax expense
३.१६ करोड
-१.७८ करोड
-१.५१ करोड
५.३९ करोड
Effective tax rate
३६.२९%
६.०६%
५०.५६%
१०१.४३%
Other operating expenses
-
-
-
-
Net income
५.४४ करोड
-२७.६६ करोड
-१.४८ करोड
-१४.८२ लाख
Net profit margin
५.४२%
-२७.८२%
-१.४९%
-०.१५%
Earnings per share
२.४३
२.३९
२.०६
३.०२
Interest and investment income
१४.२२ लाख
१०.१७ लाख
१०.३३ लाख
१०.३२ लाख
Interest expense
-२.५४ करोड
-२.३८ करोड
-२.६७ करोड
-३.०३ करोड
Net interest expenses
-२.४० करोड
-२.२८ करोड
-२.५७ करोड
-२.९३ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
२३.६२ करोड
१६.९६ करोड
२२.५७ करोड
२१.७५ करोड
Gain or loss from assets sale
-
-
११.८० करोड
२.४९ करोड
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू